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Abstract
Background: The upregulation of intercellular adhesion molecule-1 (ICAM-1) on the endothelium of blood vessels
in response to pro-inflammatory stimuli is of major importance for the regulation of local inflammation in
cardiovascular diseases such as atherosclerosis, myocardial infarction and stroke. In vivo molecular imaging of
ICAM-1 will improve diagnosis and follow-up of patients by non-invasive monitoring of the progression of
inflammation.
Results: A paramagnetic liposomal contrast agent functionalized with anti-ICAM-1 antibodies for multimodal
magnetic resonance imaging (MRI) and fluorescence imaging of endothelial ICAM-1 expression is presented. The
ICAM-1-targeted liposomes were extensively characterized in terms of size, morphology, relaxivity and the ability for
binding to ICAM-1-expressing endothelial cells in vitro. ICAM-1-targeted liposomes exhibited strong binding to
endothelial cells that depended on both the ICAM-1 expression level and the concentration of liposomes. The
liposomes had a high longitudinal and transversal relaxivity, which enabled differentiation between basal and
upregulated levels of ICAM-1 expression by MRI. The liposome affinity for ICAM-1 was preserved in the competing
presence of leukocytes and under physiological flow conditions.
Conclusion: This liposomal contrast agent displays great potential for in vivo MRI of inflammation-related ICAM-1
expression.
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Background
The vascular endothelium plays an essential role in the
regulation of the inflammatory phases of atherosclerosis
and related cardiovascular complications such as myocar-
dial infarction and stroke [1-3]. In response to local pro-
inflammatory stimuli, the endothelial expression of cell
adhesion molecules is upregulated to mediate interactions
with leukocytes circulating in the blood [4,5]. This allows
for leukocyte adhesion to the endothelium, followed by
extravasation of leukocytes through the endothelial cell
layer to the site of inflammation.
Intercellular adhesion molecule-1 (ICAM-1), a trans-
membrane immunoglobulin protein that is predominantly
expressed on endothelial cells, is of major importance in
leukocyte recruitment [6]. Upregulation of ICAM-1 contri-
butes to stable binding of leukocytes and facilitates their
transmigration by rearranging the endothelial cytoskeleton
and lowering the strength of endothelial cell junctions [7].
Non-invasive in vivo molecular imaging of endothelial
ICAM-1 expression could therefore provide valuable
insights in the progression of cardiovascular disease-related
inflammation to improve diagnosis and treatment [8].
Molecular imaging employs sophisticated contrast
agents that combine high affinity targeting ligands with
imaging labels for in vivo visualization of biological pro-
cesses at the cellular and molecular level. In this study, we
introduce a novel liposomal contrast agent functionalized
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with anti-ICAM-1 (aICAM-1) antibodies for sensitive
multimodal magnetic resonance imaging (MRI) and fluor-
escence imaging of endothelial ICAM-1 expression. MRI
enables in vivo high-resolution imaging of ICAM-1 ex-
pression in an anatomical context, whereas ex vivo fluor-
escence microscopy can be used to study the spatial
distribution of the liposomes at the tissue and cellular
level [9]. Because of the relatively large diameter of the
liposomes (100–150 nm), passive extravasation from the
blood is expected to be minimal and liposomes will be
largely confined to the blood pool, which facilitates the de-
tection of intravascular targets such as ICAM-1.
The binding of ICAM-1 targeted liposomal contrast
agents to endothelial cells was extensively studied in vitro.
Liposomes were characterized with respect to their size,
morphology, longitudinal and transversal relaxivity, and the
average number of targeting ligands per liposome was opti-
mized regarding sensitive MRI and fluorescence detection
of endothelial ICAM-1 expression. Importantly, this study
focused on various aspects that might negatively affect the
binding of liposomes to ICAM-1-expressing endothelial
cells in vivo. In the challenging intravascular environment,
ICAM-1 targeted nanoparticles have to compete with circu-
lating leukocytes for binding to ICAM-1 [4,6]. Additionally,
blood flow creates endothelial wall shear stress, which
shortens the interaction time of nanoparticles with ICAM-1
and imposes hydrodynamic forces on adherent particles,
which may result in their detachment [10,11]. Under these
conditions, a high binding affinity of ICAM-1-targeted lipo-
somes to the endothelium is crucial to enable in vivo im-
aging of ICAM-1. To address these issues, liposome
binding was investigated in vitro in the presence of leuko-
cytes and under physiologically relevant shear stress
conditions.
Results
Liposome characterization
Antibodies (Ab) were modified using N-succinimidyl S-
acetylthioacetate (SATA) and conjugated to liposomes
containing Mal-PEG-DSPE by sulfhydryl-maleimide coup-
ling. Significant binding of antibodies to liposomes was
observed for all Ab:SATA ratios used (Table 1). Paramag-
netic liposomes were successfully functionalized with
murine aICAM-1 or isotype matched non-specific IgG. In
Figure 1a representative dynamic light scattering (DLS)
spectra are shown of the size distribution of non-
functionalized liposomes (L), IgG L and aICAM-1 L, both
prepared with antibodies modified with an 80-fold excess
of SATA. A single dominant peak was observed for all
liposome preparations, indicative of a homogeneous lipo-
some size. Moreover, antibody conjugation did not signifi-
cantly alter the mean diameter of aICAM-1 L and IgG L
compared to L (Table 1).
To study liposome morphology in higher detail, cryogenic
transmission electron microscopy (cryoTEM) was performed
(Figure 1b-d). Both non-functionalized and antibody-
conjugated liposome suspensions primarily consisted of unila-
mellar, spherical liposomes, with sizes that were in line with
the DLS data.
Paramagnetic liposomes displayed MRI longitudinal and
transversal relaxivities of approximately 3.0 mM-1 s-1 and
20–55 mM-1 s-1 at 9.4 T, respectively (Table 1). The relax-
ivities were not significantly affected by liposome functio-
nalization with aICAM-1 or IgG antibodies, though there
was a large variation in the observed r2 (p> 0.05, aICAM-
1 L (1:80) and IgG L (1:80) vs. L).
Binding of liposomes to ICAM-1
The ability of aICAM-1 L, prepared using antibodies
modified with an 8- to 80-fold excess of SATA, to bind to
ICAM-1 was studied using bEnd.5 endothelial cells
expressing ICAM-1 at basal (non-activated) or upregu-
lated (TNFα-activated) levels. Non-activated and activated
cells incubated with L and various preparations of IgG L
had a low NIR-fluorescence intensity (n= 4 per group; not
shown). In contrast, binding of aICAM-1 L significantly
increased the fluorescence of activated cells up to 100-fold
as compared to IgG L. Highest fluorescence intensities, in-
dicative of the highest degree of binding, were observed
for liposomes functionalized with aICAM-1 antibodies
that were modified with an 80-fold excess of SATA (mean
fluorescence intensity = 39.0± 4.6, p< 0.05 vs. all groups)
(Figure 2a). In addition, the fluorescence of non-activated
cells was exclusively enhanced by aICAM-1 L when pre-
pared with an 80-fold excess of SATA (mean fluorescence
intensity = 3.1 ± 0.9; p< 0.05 vs. IgG L).
In Figure 2b, representative CLSM images illustrate the
cellular distribution of aICAM-1 L and IgG L (Ab:SATA=
1:80). The aICAM-1 L were mainly associated with the
cell membrane for both activated and non-activated cells.
In accordance with the fluorescence intensity measure-
ments (Figure 2a), abundant binding of aICAM-1 L to
activated cells (high ICAM-1 expression) was observed
compared to low binding to non-activated cells (basal
ICAM-1 expression). Positive secondary labeling of the
liposome-associated antibodies with fluorescent goat-anti-
rat antibodies revealed that the aICAM-1 moieties on
liposomes were available on the outside of the cell mem-
brane, thereby confirming their membrane-bound loca-
tion (Additional file 1: Figure S1). Liposomal fluorescence
was frequently observed in distinct spots (diameter = 2.5 ±
0.3 μm, measurement of 30 spots in 3 images) that were
larger than the size of individual liposomes. In contrast,
CLSM images showed low intracellular accumulation of
IgG L, which could only be detected at high laser power.
The cellular distribution of aICAM-1 L and IgG L was in-
dependent on the antibody to SATA modification ratio.
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Above results showed that aICAM-1 L prepared with an
antibody to SATA modification ratio of 1:80 had the high-
est level of association to ICAM-1 expressing bEnd.5 cells.
These liposomes had the unique ability to identify both
basal and upregulated levels of ICAM-1 expression
(p< 0.05). The liposome formulation with a 1:80 antibody
to SATA ratio was therefore used in further experiments
described below.
Table 1 Properties of L, IgG L and aICAM-1 L
antibody coupling [%] hydrodynamic diameter [nm] r1 [mM
-1 s-1] r2 [mM
-1 s-1]
NIR-liposomes
L 2.5 ± 2.8a,b 130 ± 6b 3.3 ± 0.2b 39 ± 1b
IgG L (1:8)c 64 ± 27d 140 ± 4 2.9 22
IgG L (1:20) 54 ± 18d 140 ± 9 2.8 23
IgG L (1:40) 89 ± 46d 132 ± 10 3.2 46
IgG L (1:80) 84 ± 21d 134 ± 5 2.7 ± 0.4 38 ± 6
aICAM-1 L (1:8) 52 ± 28d 137 ± 9 2.9 27
aICAM-1 L (1:20) 66 ± 20d 133 ± 16 3.3 30
aICAM-1 L (1:40) 88 ± 24d 156 ± 0d 3.1 89
aICAM-1 L (1:80) 83 ± 9d 141 ± 2 2.7 ± 0.4 53 ± 16
Rhodamine-liposomes
L −0.8 ± 0.8a 133 ± 5 4.2 ± 0.8 54 ± 8
aICAM-1 L (1:80) 98 ± 4d 163 ± 2 3.3 ± 0.1 53 ± 15
Liposomes contained either a NIR or a rhodamine fluorophore. n = 1-5; a baseline value indicative for the inaccuracy of the protein assay; b mean ± SEM; c (1:x) the
applied molar ratio of Ab: SATA; d = p< 0.05 vs. L, ANOVA with LSD correction for NIR-liposomes and t-test for rhodamine-liposomes.
Figure 1 Characterization of the liposomes by DLS and cryoTEM. (a) Representative DLS size distributions of L, IgG L (Ab:SATA= 1:80) and
aICAM-1 L (Ab:SATA= 1:80) that were prepared from a single batch of liposomes. The three types of liposomes display a similar narrow size
distribution. CryoTEM was used to study the morphology of (b) L, (c) IgG L (Ab:SATA= 1:80) and (d) aICAM-1 L (Ab:SATA= 1:80). Lipid suspensions
were mainly composed of single unilamellar liposomes. Scale bar = 500 nm.
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Liposome concentration-dependence of ICAM-1 binding
The binding of liposomes to endothelial cells as function
of the concentration of liposomes in the incubation
medium was determined at 4 °C to minimize liposome
internalization and ICAM-1 recycling for accurate evalu-
ation of the liposomal ICAM-1 binding interactions.
Under these conditions, the NIR-fluorescence intensity
of TNFα-activated bEnd.5 cells depended on the con-
centration of aICAM-1 L in the incubation medium
(Figure 3a), but not on the concentration of IgG L
(Figure 3b). The mean fluorescence intensity of both
activated and non-activated endothelial cells linearly
related to the concentration of aICAM-1 L (R2 = 0.99),
indicating that ICAM-1 binding was not saturated
within the concentration range studied (Figure 3c). In
contrast, application of IgG L at concentrations up to 2
mM lipid did not result in significant binding to endo-
thelial cells (Figure 3c). Importantly, the binding of
aICAM-1 L to activated cells was significantly higher
than to non-activated cells (linear slope of 4.0 versus
1.0), proving that the association of aICAM-1 L was also
related to the level of ICAM-1 expression.
The minimal aICAM-1 L concentration required to de-
tect upregulated levels of ICAM-1 expression on activated
cells using fluorescence activated cell sorting (FACS) was
0.125 mM lipid, whereas 0.5 mM lipid was needed to
Figure 2 Binding of aICAM-1 L to non-activated and TNFα-
activated bEnd.5 cells. (a) Cellular NIR fluorescence intensity of
non-activated and TNFα-activated bEnd.5 cells after 2 h incubation
at 37 °C with aICAM-1 L, prepared using different Ab:SATA ratios,
quantified with FACS. Data were corrected for cellular fluorescence
after incubation with L and reflect the increase in fluorescence by
aICAM-1 conjugation. Application of IgG L did not lead to an
increase in fluorescence intensity (not shown). * = p< 0.05 vs. all
groups, ** = p< 0.05 vs. IgG L, ANOVA with Bonferroni correction.
n = 3-4. (b) CLSM images illustrating the cellular distribution of
aICAM-1 L (Ab:SATA= 1:80) and IgG L (Ab:SATA= 1:80) (red). The cell
membrane was labeled with CD31 (green) and cell nuclei were
counterstained with DAPI (blue). Laser power 488 nm: 25%, 780 nm:
4%, 633 nm, IgG L: 50%, aICAM-1 L/-TNFα: 10% and aICAM-1
L/+TNFα: 5%. Scale bar = 50 μm. Figure 3 Binding of aICAM-1 L and IgG L to bEnd.5 cells with
varying lipid concentration. Representative FACS spectra of NIR
fluorescence of TNFα-activated bEnd.5 cells after 30 min incubation
at 4 °C with (a) aICAM-1 L and (b) IgG L at different liposome
concentrations. (c) Mean fluorescence intensity of non-activated and
TNFα-activated bEnd.5 cells after incubation with IgG L or aICAM-1 L
at liposome concentrations varying from 0.0625-2 mM lipid.
* = p< 0.05 vs. IgG L, ** = p< 0.05 vs. aICAM-1 L/-TNFα, t-test. n = 3
for aICAM-1 L, n = 1 for IgG L.
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identify the basal ICAM-1 expression levels on non-
activated cells (p< 0.05 aICAM-1 L vs. IgG L). Cellular
fluorescence was significantly higher for activated cells as
compared to non-activated cells when incubated with
aICAM-1 L at lipid concentrations of 0.25 mM and
higher.
MRI detection sensitivity
To enable MR-imaging of ICAM-1 expression, paramag-
netic aICAM-1 L must specifically and significantly de-
crease the MR relaxation time parameters. Representative
T1 and T2 maps obtained at 9.4 T (Figure 4a) demon-
strated the ability of aICAM-1 L to reduce the relaxation
times of cells compared to native cells or those incubated
with control liposomes (IgG L or L). This can be recog-
nized from the much brighter color in pellet number 4.
From these T1 and T2 maps, the mean cellular R1 and R2
were calculated (Figure 4b, c). The R1 and R2 of TNFα-
activated cells were significantly increased by aICAM-1 L
(1.8± 0.1 s-1 and 78± 4 s-1, respectively) with respect to
controls. Importantly, a significant (but smaller) increase
in R1 and R2 was also observed for non-activated cells
incubated with aICAM-1 L (0.75 ± 0.07 s-1 and 39± 4 s-1,
respectively). Application of control liposomes (IgG L and
L) did not alter the cellular R1 or R2 (p> 0.05). Import-
antly, aICAM-1 L enabled MRI to distinguish between
cells with basal and upregulated levels of ICAM-1 expres-
sion (p< 0.05).
Figure 4d illustrates that the increase in the relaxation
rates of cells incubated with aICAM-1 L was consistent
with a significant association of gadolinium with activated
cells (0.84 ± 0.18 mM Gd) and non-activated cells
(0.20± 0.08 mM Gd) compared to control liposomes.
Interestingly, the effective relaxivities r1 and r2 of cells
incubated with aICAM-1 L, which were estimated from
the MR-relaxation rates and gadolinium concentrations,
were also dependent on the ICAM-1 expression level. The
r1 improved from 1.2 ± 0.2 mM
-1 s-1 to 1.7 ± 0.5 mM-1 s-1
for cells with basal and upregulated ICAM-1 expression,
respectively, whereas the r2 increased from 42±6 mM
-1 s-1
to 103±16 mM-1 s-1 (p< 0.05). We hypothesize that the
increased cellular relaxivity for upregulated levels of
ICAM-1 is due to increased immobilization of the lipo-
somes on the cell membrane by steric hindrance.
Competition from leukocytes
In vivo imaging of ICAM-1 expression on inflamed
endothelium by aICAM-1 L may be hampered by the
presence of circulating leukocytes, which compete with
liposomes for binding to ICAM-1. Additionally, leuko-
cytes might phagocytose liposomes, making them unavail-
able for binding to endothelial ICAM-1. To investigate
these interactions in vitro, endothelial cells were co-
incubated with liposomes and leukocytes that constitu-
tively express CD11b and CD18 (Additional file 2: Figure
S2), a receptor pair which binds ICAM-1.
Figure 4 MRI characterization of bEnd.5 cells incubated with non-targeted and ICAM-1 targeted liposomes. (a) Representative T1 and T2
maps of non-activated and TNFα-activated bEnd.5 cells, incubated for 2 h at 37 °C with 1) no liposomes, 2) L, 3) IgG L and 4) aICAM-1 L. Cellular
(b) R1 and (c) R2 measured at 9.4 T. (d) Concentration of gadolinium associated with bEnd.5 cells determined with ICP-MS. * = p< 0.05 vs. all
groups, ** = p< 0.05 vs. all non-activated groups, ANOVA with Bonferroni correction. n = 4.
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The FACS scatter plots in Figure 5a-c reveal that the
NIR-fluorescence of TNFα-activated endothelial cells
incubated with aICAM-1 L slightly decreased with in-
creasing concentration of leukocytes. More extensively, in
Figure 5d the mean fluorescence intensity originating
from aICAM-1 L and IgG L bound to either activated or
non-activated endothelial cells is shown for increasing
leukocyte concentrations. A moderate, but significant de-
cline in endothelial fluorescence from 76.5 ± 3.0 (no leuko-
cytes) to 65.2± 1.9 (2x105 leukocytes/ml) and 55.6 ± 1.5
(1x106 leukocytes/ml) was observed for aICAM-1 L, indi-
cating that leukocytes indeed reduced the association of
aICAM-1 L with activated endothelium. Nevertheless, the
fluorescence of activated endothelial cells was strongly
enhanced by aICAM-1 L compared to IgG L, regardless of
the presence of leukocytes (p< 0.05). The ability of
aICAM-1 L to bind to non-activated endothelial cells was
not compromised by leukocytes, as the endothelial fluor-
escence was independent on the concentration of leuko-
cytes in this case (Figure 5d).
Importantly, leukocytes exhibited massive accumulation
of IgG L and aICAM-1 L, as illustrated in Figure 5e, in
which the mean leukocyte fluorescence intensity is shown.
Upon incubation with IgG L, the fluorescence of leukocytes
was increased 135-fold compared to endothelial cells (com-
pare Figure 5d and Figure 5e). Additionally, leukocyte fluor-
escence was significantly higher when cells were incubated
with aICAM-1 L (116±3) compared to IgG L (95.0±0.8),
which is in accordance with the expression of ICAM-1 by
leukocytes (Additional file 2: Figure S2). The association of
liposomes with leukocytes was independent of the presence
of endothelial cells, both for non-activated and activated
endothelial cells.
Liposomal ICAM-1 binding under shear stress conditions
The in vivo binding of aICAM-1 L to vascular endothe-
lium requires fast and strong interactions with ICAM-1
to resist the continuous shear stress generated by blood
flow. Therefore, the binding potential of aICAM-1 L was
studied under physiologically relevant wall shear stress
values up to 0.5 Pa in vitro [12]. Fluorescence micros-
copy images of TNFα-activated endothelial cells incu-
bated with L (0 Pa) and aICAM-1 L (0, 0.25 and 0.5 Pa)
are shown in Figure 6a. Fluorescence originating from
binding of aICAM-1 L was detected at all applied shear
stress values, whereas no significant fluorescence was
observed after application of L. However, shear stress
elevation resulted in a reduction of the fluorescence of
Figure 5 Binding of aICAM-1 L to bEnd.5 in the competing presence of leukocytes. Non-activated and TNFα-activated bEnd.5 cells
incubated for 2 h at 37 °C with IgG L or aICAM-1 L in the presence of 0, 2.5x105 or 1x106 leukocytes/ml medium. (a-c) Typical FACS scatter plots
of liposomal NIR-fluorescence vs. GRN (green) fluorescence to distinguish TNFα-activated bEnd.5 cells from RAW cells labeled with calcein (green).
(d) Endothelial NIR fluorescence intensity. * = p< 0.05 vs. all groups, ANOVA with Bonferroni correction. (e) Leukocyte NIR fluorescence intensity.
* = p< 0.05 vs. IgG L, ANOVA with Bonferroni correction. n = 3, except for aICAM-1 L/-TNFα n= 1.
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aICAM-1 L, indicative of decreased binding to ICAM-1,
compared to static conditions.
After harvesting the cells from the flow chamber, the
fluorescence intensity was quantified by FACS (Figure 6b).
The application of flow reduced the ability of aICAM-1 L
to adhere to ICAM-1 on endothelial cells, as evidenced by
a significant decrease in cellular fluorescence from 6.9±0.7
(0 Pa) to 2.1±0.1 (0.25 Pa) and 1.3±0.1 (0.5 Pa). A con-
founding factor could be that wall shear stress altered the
ICAM-1 expression levels. Fluorescent evaluation of
ICAM-1 expression showed that ICAM-1 expression levels
were increased at shear stress levels of 0.25 Pa and 0.5 Pa
(Figure 6c), in agreement with previous findings [13,14].
Therefore, the reduction of nanoparticle binding under flow
conditions is somewhat higher than the numbers indicate.
Nevertheless, the binding of aICAM-1 L to endothelial cells
remained significantly higher than of L at both shear stress
levels.
Discussion
Excessive recruitment of leukocytes to sites of atheroscler-
osis, myocardial infarction or stroke is implicated in adverse
disease progression [15,16]. Clinical treatment decision-
making might therefore substantially benefit from in vivo
imaging readouts of the local inflammatory status. The
in vivo MR-imaging of cell adhesion molecules expressed
on inflamed vascular endothelium is of particular interest,
considering their crucial role in mediating leukocyte ex-
travasation [4]. Previous studies have demonstrated that tar-
geted iron-oxide-based MR-contrast agents are able to
create hypo-intense signals on T2
*-weighted images in
regions of VCAM-1 or P-selectin expression in mouse
models of atherosclerosis and brain inflammation [17-19].
Alternatively, the use of targeted Gd-based probes, which
create signal hyperenhancement on T1-weighted images,
has been explored as well [20-22]. Choi et al. used anti-
ICAM-1 antibodies decorated with Gd-DTPA moieties to
highlight muscular inflammation on in vivo MRI, whereas
Sipkins et al. performed ex vivo MRI to visualize brain in-
flammation using paramagnetic liposomes [20,21]. In this
study, a novel paramagnetic ICAM-1-targeted liposomal
contrast agent was designed and, importantly, its inter-
action with ICAM-1 was studied in vitro under conditions
that mimic the challenging environment encountered in
the circulation.
Liposomes containing Gd-DOTA-DSPE previously have
been characterized with respect to their MRI properties at
1.4 T, which is close to a clinical field strength of 1.5 T [23].
At 1.4 T, Gd-DOTA-DSPE liposomes have a high longitu-
dinal relaxivity compared to frequently used Gd-DTPA-
BSA liposomes, which is caused by improved water access
to Gd by the use of a small linker between DSPE and
DOTA as well as by the different exchange dynamics of
water bound to the Gd ion that is much faster for the tetra-
Figure 6 Binding of aICAM-1 L to bEnd.5 in the competing
presence of shear stress. TNFα-activated cells incubated with L or
aICAM-1 L for 2 h at 37 °C and shear stress values of 0, 0.25 or
0.5 Pa. (a) Fluorescence microscopy of rhodamine lipids in
liposomes adherent to bEnd.5 cells (red). Scale bar = 100 μm. (b)
Cellular rhodamine fluorescence intensity quantified with FACS.
* = p< 0.05 vs. all groups, ANOVA with Bonferroni correction,
** = p< 0.05 vs. IgG L, t-test. n = 2-5. (c) ICAM-1 expression at
different shear stress levels. * = p< 0.05 vs. 0 Pa, ANOVA with
Bonferroni correction. n = 3.
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carboxylate DOTA ligand than for the bis-carboxoamide
linear DTPA ligand [23,24]. A high longitudinal relaxivity
will facilitate sensitive detection of the Gd-DOTA-DSPE
liposomes. At the high preclinical field strength used in this
study (9.4 T) one cannot fully exploit this high longitudinal
relaxivity. Nevertheless, relaxivity numbers are expressed in
terms of relaxivity per Gd atom and the very high payload
of Gd (~105 Gd per liposome) results in much higher relax-
ivity values per nanoparticle and thus sensitive detection on
T1-weighted images [25]. A possible drawback of the use of
these liposomes is the enhanced r2/r1 ratio at 9.4 T, which
might introduce a considerable T2-weighting in the images.
However, by carefully choosing the MR-imaging para-
meters, T2 effects can be minimized to make optimal use of
the T1-lowering properties of liposomes.
The binding of liposomes to ICAM-1 expressing endo-
thelial cells was optimized by improving the coupling of
aICAM-1 antibodies by increasing the extent of antibody
thiolation. The antibody-coupling efficacy was enhanced by
30-60% using an 80-fold excess of SATA compared to an 8-
fold excess. The 1:80 antibody to SATA modification ratio
resulted in a liposomal antibody density of 960–1200 Ab/
μm2, which compares well to recent studies using ICAM-1
targeted polystyrene beads or ultrasound microbubbles
[11,26,27]. The ability of aICAM-1 L to adhere to ICAM-1
expressing endothelial cells was not compromised by the
extensive antibody thiolation (Figure 2a). Furthermore, the
association of aICAM-1 L with endothelial ICAM-1 varied
linearly with the concentration of liposomes (Figure 3c) and
did not saturate within a physiologically relevant range (up
to 2 mM lipid). This agrees with earlier studies using fluor-
escent liposomes where ICAM-1 binding was only satu-
rated at higher liposome concentrations (5 to 12 mM lipid)
[28,29]. Importantly, the binding of aICAM-1 L was
dependent on the level of ICAM-1 expression on the endo-
thelial cell membrane (Figures 2a, 3c), which is encouraging
for the use of aICAM-1 L for quantitative in vivo MR-
imaging of ICAM-1.
The sensitivity of MRI at 9.4 T was sufficient to differ-
entiate between basal and upregulated levels of ICAM-1
expression in vitro based on the MR relaxation rates of
endothelial cells after binding of paramagnetic aICAM-1 L
(Figure 4b, c). Interestingly, the contribution of aICAM-1 L
to the cellular R1 was larger than to the R2, despite
the high r2/r1 ratio of liposomes in buffer at 9.4 T.
This pronounced effect of aICAM-1 L on endothelial cell
R1 will facilitate the detection of ICAM-1 expression on
vascular endothelium in vivo with T1-weighted MRI. Add-
itionally, this finding indicated that the longitudinal relax-
ivity of aICAM-1 L could be fully exploited and was not
restricted by limited water exchange as a result of
internalization and subsequent compartmentalization of
liposomes into endosomes, as was previously observed for
αvβ3-targeted liposomes [30,31]. CLSM indeed showed
that aICAM-1 L were not internalized, but were mainly
bound to the extracellular side of the cell membrane
(Additional file 1: Figure S1) – a distinct advantage to other
ICAM-1 specific nanoparticles [29,32,33]. Previously,
though, Mastrobattista et al. have shown internalization of
ICAM-1 targeted liposomes by human lung epithelial cells,
indicating that the human ICAM-1 receptor is able to
internalize liposomes [29]. Moreover, Muro et al. have
performed extensive studies on the internalization
pathway of ICAM-1 targeted nanometer and microm-
eter sized fluorescent particles to clarify the exact
mechanism for ICAM-1 mediated internalization in endo-
thelial cells [32-34]. The observed lack of internalization of
aICAM-1 L in our study could also be related to dif-
ferences in the condition of bEnd.5 endothelial cells
compared to human umbilical vein or lung epithelial
cells used in other studies, thereby resulting in an
inability to internalize aICAM-1 L through cell-adhesion-
molecule-mediated endocytosis.
In vitro competition experiments showed that the associ-
ation of aICAM-1 L with ICAM-1 on endothelial cells was
lowered in the presence of leukocytes (Figure 5d). This is
probably related to occupation and steric hindrance of
ICAM-1 receptors by the CD11b/CD18-expressing leuko-
cytes. In vivo, partial blocking of ICAM-1 receptors on
inflamed endothelium by leukocytes could result in an
underestimation of the ICAM-1 expression level by
aICAM-1 L. Moreover, both aICAM-1 L and IgG L were
internalized by phagocytotic leukocytes in vitro (Figure 5e).
This might cause false positive non-specific MR-signal en-
hancement in vivo by extravasation of liposome-laden leu-
kocytes at sites of inflammation. Nevertheless, in the
circulation quiescent leukocytes require activation by local
inflammatory stimuli and therefore blood-pool accumula-
tion of liposomes in leukocytes is expected to be low.
The capacity of aICAM-1 L to bind to endothelial cells
lining the vasculature could be affected by blood flow,
which reduces the interaction time for liposome binding
and imposes torque and shear forces on the adherent lipo-
somes, as was previously observed for targeted fluorescent
microbeads and ultrasound microbubbles [10,11,34-36].
In this study, in vitro binding of aICAM-1 L to ICAM-1
was reduced with increasing shear stress within a physio-
logically relevant range (Figure 6b) [12]. Nevertheless, the
ability of aICAM-1 L to bind to endothelial cells in the
microcirculation in vivo might be improved by the effect
that erythrocytes preferentially occupy the center of blood
vessels, thereby increasing the effective liposome concen-
tration near the vessel wall and enhancing their probabil-
ity to interact with the endothelium [37]. Furthermore,
there are several options to improve the binding of
aICAM-1 L to endothelial cells. Recently, Calderon et al.
observed improved interaction kinetics and total bond
strength of ICAM-1-targeted microbeads with endothelial
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cells, when increasing the nanoparticle’s antibody density
from 1100 Ab/μm2 to 4100 Ab/μm2 [11]. This is probably
related to an increased multivalency of nanoparticle-
endothelial cell interactions. Furthermore, incorporation
of PEG-polymers in the liposome bilayer, as used in our
liposome formulation, may have a positive effect on the
aICAM-1/ICAM-1 interaction strength. PEG is capable of
enhancing the bond lifetime between ligands on nanopar-
ticles and their corresponding receptors on cells under
hydrodynamic conditions by increasing the bond flexibility
[38]. Moreover, liposomes might be functionalized with
more than one type of targeting ligand to optimize endo-
thelial cell association under flow conditions, as previously
shown for VCAM-1 and P-selectin targeted microbubbles
by Ferrante et al. [26,39].
Conclusions
In this study, a high-relaxivity ICAM-1-binding liposo-
mal MR-contrast agent was developed that 1) showed
strong binding to endothelial cells that depended on
both the ICAM-1 expression level and the concentration
of liposomes, 2) could distinguish between basal and
upregulated levels of ICAM-1 expression by MRI and 3)
displayed significant binding to endothelial ICAM-1
even in the competing presence of leukocytes and under
physiological flow conditions. Taken together, the ability
of ICAM-1 targeted liposomes to bind ICAM-1 under
these harsh conditions might allow this contrast agent to
visualize ICAM-1 in a variety of cardiovascular and
neurological diseases using in vivo MR-imaging.
Methods
Liposome preparation
Liposomes were composed of 1,2-distearoyl-sn-glycero
-3-phosphocholine (DSPC, Lipoid, Steinhausen, Switzer
land), cholesterol (Avanti Polar Lipids, Alabaster, USA),
gadolinium-DOTA-1,2-distearoyl-sn-glycero-3-phosphoe
thanolamine (Gd-DOTA-DSPE, SyMO-Chem, Eindho-
ven, the Netherlands), DSPE-N-[methoxy(poly(ethylene-
glycol))2000] (PEG-DSPE, Lipoid), DSPE-N-[maleimide
\(poly(ethyleneglycol))2000] (Mal-PEG-DSPE, Avanti Polar
Lipids) and near-infrared664-DSPE (NIR664-DSPE, SyMO-
Chem) or 1,2-dipalmitoyl-sn-glycero-3-phosphoethanola-
mine-N-(lissamine rhodamine B sulfonyl) (rhodamine-PE,
Avanti Polar Lipids) in a molar ratio of 1.1:1:0.75:0.075:0
.075:0.003. Lipid films were prepared by rotary evaporation
(30 °C) of 50 μmol lipid dissolved in chloroform and
methanol (8:1 v/v), with additional drying under N2. To ob-
tain liposomes, lipid films were hydrated at 65 °C for
10 min in 8 ml HEPES-buffered saline (HBS, pH 6.7), com-
posed of 10 mM HEPES and 135 mM NaCl, followed by
extrusion at 65 °C through polycarbonate membrane filters
of 400 nm (2x) and 200 nm (10x) [23].
Liposome functionalization with antibodies
Monoclonal mouse aICAM-1 and isotype-matched control
IgG antibodies (clone YN1/1.7.4 and RTK4530, BioLegend,
Uithoorn, the Netherlands) were covalently coupled to Mal-
PEG-DSPE through thioether linkage to obtain aICAM-1 lipo-
somes (aICAM-1 L) and IgG liposomes (IgG L), respectively
[40]. For this purpose, acetylthioacetate moieties were intro-
duced on antibodies by modification with N-succinimidyl S-
acetylthioacetate (SATA, Sigma-Aldrich, Zwijndrecht, the
Netherlands) for 40 min at room temperature (RT). Various
molar ratios of Ab:SATA (1:8, 1:20, 1:40 and 1:80) were tested
to optimize antibody coupling to liposomes. Free SATA was
removed by washing in HBS (pH 6.7) on a Vivaspin concen-
trator (30 kDa cut-off) by centrifugation at 3000 g and 4 °C.
Acetylthioacetate groups were converted into free thiols by
deacetylation with hydroxylamine (pH 7.0) for 1 h (RT). Dir-
ectly thereafter, antibodies and liposomes were mixed at 50 μg
protein/μmol lipid at 4 °C under N2. Coupling of the anti-
bodies to liposomes continued overnight, after which the lipo-
somes were diluted in HBS (pH 7.4). Liposomes were
separated from non-conjugated antibodies by ultracentrifuga-
tion (55,000 rpm; 45 min; 4 °C). Liposomes were resuspended
in HBS (pH 7.4) to a final concentration of 50–70 mM lipid
and stored at 4 °C until further use.
Liposome characterization
Liposomal phospholipid concentration was quantified
with a phosphate determination according to Rouser [41].
Antibody coupling efficacy to liposomes was determined
by a Lowry-based protein assay (Bio-Rad, Veenendaal, the
Netherlands), corrected for the presence of lipids [42].
The average hydrodynamic number-weighted diameter
and size distribution of the liposomes were estimated by
DLS of a 633 nm laser on a Zetasizer Nano S (Malvern
Instruments, Worcestershire, UK) at RT.
Liposome morphology was evaluated with cryoTEM.
Samples were vitrified on carbon-coated cryoTEM grids
with a vitrification robot (Vitrobot Mark III, FEI, Hillsboro,
USA). Imaging was performed on a Tecnai 20 Sphera TEM
instrument (FEI) equipped with a LaB6 filament (200 kV)
and Gatan cryoholder (approximately −170 °C) at 6500x
magnification.
Liposomal longitudinal and transversal relaxation times
(T1 and T2) were determined with a 9.4 T horizontal bore
scanner (Bruker BioSpin GmbH, Ettlingen, Germany) using
a 35-mm-diameter quadrature RF-coil (Rapid Biomedical,
Rimpar, Germany). T1 was obtained with an inversion-
recovery segmented FLASH sequence with TR=15 s and
TI=72.5-4792.5 ms (60 inversion times). For T2 measure-
ments, a spin echo sequence was used with TR=2 s and
TE=9-288 ms (32 echoes). Quantitative T1 and T2 values
were obtained by fitting the MR-data with mono-exponential
relaxation curves in Mathematica 6 (Wolfram Research Eur
ope, Oxfordshire, UK). Relaxivities (r1 and r2 in mM
-1 s-1)
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were determined from Ri=Ri,0 + ri[Gd], with i 2 {1,2}, Ri=1/
Ti, Ri,0 =Ri of sample without liposomes and [Gd] varying
from 0.01-1 mM Gd. Relaxivities are expressed in terms of
Gd concentration rather than nanoparticle concentration.
Cell culture
Mouse brain endothelioma cells, bEnd.5 (European Collec-
tion of Animal Cell Cultures (ECACC)), were cultured in
low glucose DMEM, supplemented with 10% fetal bovine
serum (FBS) and 5 μM 2-mercaptoethanol. The bEnd.5 cells
display a basal expression of ICAM-1. ICAM-1 expression
was upregulated by 24 h activation with 40 ng/ml recombin-
ant tumor necrosis factor-α (TNFα, PeproTech EC Ltd.,
London, UK) as shown in Additional file 3: Figure S3. Mouse
leukocytes, RAW 264.7 (ECACC), were maintained in RPMI
medium, containing 10% FBS, 2 mM L-glutamine and 105
U/l penicillin/streptomycin. Prior to experiments, RAW cells
were fluorescently labeled with 1 μM calcein AM (Invitro-
gen, Bleiswijk, the Netherlands) for 30 min (37 °C). Excess
calcein was removed by centrifugation (2x5 min, 500 g).
Liposomal ICAM-1 binding under static conditions
The ability of aICAM-1 L to specifically bind to non-activated
and TNFα-activated bEnd.5 cells was first investigated under
static incubation conditions. To identify the liposome formula-
tion with highest level of ICAM-1 binding, cells were incubated
for 2 h at 37 °C with aICAM-1 L or IgG L, prepared with vari-
ous ratios of Ab:SATA, or non-functionalized liposomes (L) at a
concentration of 1 mM lipid. Afterwards, cells were washed
with medium and phosphate buffered saline (PBS) to remove
non-bound liposomes. For fluorescence intensity quantification,
cells were harvested with trypsin/EDTA, fixed in 4% parafor-
maldehyde (PFA) and stored in 0.01% sodium-azide, whereas
for confocal laser scanning microscopy (CLSM) cells cultured
in microscopy chambers (Ibidi GmbH, München, Germany)
were fixed in 4% PFA and stored in PBS. Prior to CLSM, cell
membranes were labeled with biotin rat anti-mouse CD31
(10 μg/ml, BioLegend) conjugated to streptavidin-fluorescein
isothiocyanate (FITC) (5 μg/ml, BioLegend). Cell nuclei were la-
beled with 0.1 μg/ml 4’6-diamidino-2-phenylindole dihy-
drochloride (DAPI, Invitrogen). In separate samples, goat anti-
rat Alexa488 (10 μg/ml, Invitrogen) was added to visualize
extracellularly located antibody-conjugated liposomes.
The relation between the liposome concentration in the
incubation medium and the extent of liposome binding to
ICAM-1 was studied at 4 °C to inhibit internalization of
ICAM-1-liposome complexes. Non-activated and TNFα-
activated cells were incubated for 30 min at 4 °C with vari-
ous concentrations of aICAM-1 L or IgG L (0.0625-2 mM
lipid). Non-bound liposomes were removed by washing
and cells were processed for fluorescence intensity quanti-
fication as described above.
To determine the sensitivity of MRI to detect basal and
upregulated levels of ICAM-1 expression, non-activated
and TNFα-activated cells were incubated for 2 h at 37 °C
with aICAM-1 L, IgG L or L (1 mM lipid). Next, cells
were washed, harvested and fixed in 4% PFA. A loosely
packed cell pellet was allowed to form at 4 °C.
Competition from leukocytes
The binding of liposomes to endothelial cells was also
evaluated in the competing presence of leukocytes by co-
incubation of non-activated or TNFα-activated bEnd.5
cells (2 h at 37 °C) with 0, 2x105 or 1x106 calcein-labeled
RAW cells/ml and aICAM-1 L or IgG L (1 mM lipid). To
study direct interactions of leukocytes with liposomes,
RAW cells were incubated for 2 h at 37 °C with aICAM-
1 L or IgG L (1 mM lipid) in the absence of bEnd.5 cells.
After incubation, cells were washed and samples were pre-
pared for fluorescence intensity quantification. To deter-
mine ICAM-1, CD11b and CD18 expression levels on
RAW cells, cells were labeled by rat anti-mouse antibodies
against ICAM-1 (10 μg/ml) conjugated to goat anti-rat
Cy3 (5 μg/ml), biotin CD11b (10 μg/ml) in combination
with streptavidin-Cy3 (5 μg/ml) or CD18 R-phycoerythrin
(PE) (4 μg/ml) (all antibodies from BioLegend).
Liposomal ICAM-1 binding under shear stress conditions
The effect of shear stress on the ability of aICAM-1 L to as-
sociate with endothelial ICAM-1 was studied with a unidir-
ectional flow system (Ibidi GmbH) [43]. The system was
calibrated at a shear stress of 0.25 Pa and 0.5 Pa, taking into
account the viscosity of medium containing liposomes
(η=0.75 mPas at both shear stress values). The bEnd.5
cells were cultured and activated with TNFα on flow cham-
ber microscopy slides (50x5x0.8 mm3 μ-slide, Ibidi GmbH)
under static conditions. Subsequently, TNFα-activated
bEnd.5 cells were incubated with aICAM-1 L or L (1 mM
lipid) at a constant shear stress of 0, 0.25 or 0.5 Pa in closed
flow chambers at 37 °C. After 2 h, cells were washed and
the rhodamine fluorescence of adherent liposomes was
evaluated with a Leica DMI 3000B microscope (Leica
Microsystems, Rijswijk, Netherlands) equipped with a Leica
EL6000 light source and 590 nm long pass filter. After-
wards, samples were prepared for fluorescence intensity
quantification. To evaluate ICAM-1 expression at different
flow rates, cells were labeled with rat anti-mouse ICAM-1
(20 μg/ml) and goat anti-rat Alexa488 (40 μg/ml).
Cellular fluorescence intensity
The fluorescence intensity of cell-associated rhodamine-
or NIR664-lipids and fluorescently labeled antibodies was
quantified by FACS on a Guava EasyCyte 8HT (Millipore,
Billerica, USA). NIR664 was excited with a 640 nm laser
and detected using a 661/19 nm band pass (BP) filter.
Rhodamine, Cy3 and PE were detected with a 488 nm
laser combined with a 583/26 nm BP filter, whereas
calcein-labeled RAW cells and Alexa488 were captured
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with a 525/30 BP filter. Mean cellular fluorescence inten-
sity was determined with Kaluza 1.0 software (Beckman
Coulter) and was corrected for cellular autofluorescence,
unless mentioned otherwise.
Cellular distribution of liposomes
The cellular location of the liposomes was studied with
CLSM. NIR664-lipids were visualized with an LSM 510
META system (Carl Zeiss B.V., Sliedrecht, Netherlands)
equipped with a 633 nm HeNe laser (5.0 mW) in combin-
ation with a 680/60 nm BP filter. Cell membranes and
extracellular liposomes labeled with Alexa488 were
detected with a 488 nm argon laser (13.5 mW) using a
525/50 nm BP filter. A Ti:Sapphire laser tuned to 780 nm
(2925.0 mW) was used for two-photon excitation of DAPI,
whose fluorescence was captured with a 460/50 BP filter.
All images were acquired with a 63x oil immersion object-
ive at 0.07x0.07 μm2 in-plane resolution (2048x2048
matrix, 4 averages).
Cellular relaxation rates and relaxivities
Cellular relaxation rates (R1 and R2) were determined at
9.4 T as described above. Cellular relaxivities (r1 and r2)
were calculated according to Ri =Ri,0 + ri[Gd], with i 2
{1,2}, Ri,0 =Ri of cells incubated without liposomes. To
quantify gadolinium concentrations, the volume of the cell
pellets was obtained from 3D FLASH MR-images (9.4 T;
TR=25 ms; TE=3.7 ms; flip angle =30o; 100 μm3 isotropic
resolution) with Osirix Software (www.osirix-viewer.com),
whereas the gadolinium content was quantified by induct-
ively coupled plasma mass spectrometry (ICP-MS) using a
DRCII (Perkin Elmer, Waltham, USA) after destruction in
1:2 (v/v) nitric acid and perchloric acid at 180 °C.
Statistics
One-way analysis of variance (ANOVA) with Bonferroni
correction for multiple group comparisons and ANOVA
with LSD correction or Student’s t-test for comparison
between two groups were used to test for significant dif-
ferences (p< 0.05). Data were presented as mean ± SEM.
Additional files
Additional file 1: Figure S1. CLSM images of activated bEnd.5 cells
incubated with aICAM-1 L (Ab:SATA = 1:80). (left) NIR fluorescence from
the liposomes in red. (middle) In green, fluorescence from extracellularly
located antibodies labeled with goat anti-rat Alexa488. (right) Merged
image shows the co-localization (yellow) of aICAM-1 L (red) and
Alexa488- IgG (green), thereby confirming the extracellular location of
aICAM-1 L. Laser power 488 nm: 3%, 633 nm: 5%. Scale bar = 50 μm.
Additional file 2: Figure S2. ICAM-1, CD11b and CD18 expression
levels on RAW cells quantified with FACS. Fluorescence intensities were
corrected for non-specific binding of goat anti-rat Cy3. n = 1.
Additional file 3: Figure S3. ICAM-1 and CD31 expression levels on
non-activated (−TNFα) and activated (+TNFα) bEnd.5 cells quantified with
FACS. Fluorescence intensities were corrected for non-specific binding of
goat anti-rat Alexa488. The fluorescence of non-activated cells labeled
with aICAM-1 antibodies did not exceed the fluorescence of cells
incubated with goat anti-rat Alexa488 only. n = 3 for ICAM-1 and n = 1 for
CD31. * = p< 0.05 vs. –TNFα/ICAM-1, t-test.
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